Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 26 (1) , 13-21
- https://doi.org/10.2165/00002018-200326010-00002
Abstract
The present review outlines the clinical relevance of pharmacokinetic drug interactions within the HMG-CoA reductase inhibitor class. These interactions can result in markedly increased or decreased...Keywords
This publication has 47 references indexed in Scilit:
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Safety and Tolerability of Pravastatin in Long-Term Clinical TrialsCirculation, 2002
- Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and SimvastatinAntimicrobial Agents and Chemotherapy, 2001
- Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomesBritish Journal of Clinical Pharmacology, 2001
- Concomitant use of cytochrome P450 3A4 inhibitors and simvastatinThe American Journal of Cardiology, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients: Are the Statins Mechanistically Similar?Pharmacology & Therapeutics, 1998
- Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatinBritish Journal of Clinical Pharmacology, 1998
- EVALUATION OF FLUVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN RENAL TRANSPLANT RECIPIENTS TAKING CYCLOSPORINE1Transplantation, 1996
- Diltiazem myopathyAmerican Heart Journal, 1993